We therefore wanted to assess whether ILC2 cells in NSCLC patients may have immunosuppressive capacities by interacting directly with CD4+ T cells via MHC II, CD86 and PD-L1. This evidence concerns the gene CD4 and non-small cell lung carcinoma.